Richard Z. Lin

Richard Z. Lin, M.D.

Associate Professor

Departments of Medicine and Physiology & Biophysics

M.D., University of California at San Francisco
Medicine Residency, Stanford University Medical Center
Hematology Fellowship, Stanford University Medical Center

Member: Institute of Molecular Cardiology; Molecular & Cellular Biology Ph.D Graduate Program

Address: HSC T15-045, Stony Brook University, Stony Brook, NY 11794-8151
Phone: 631-444-2059
email: richard.lin@sunysb.edu

Lab Members:
Lisa Ballou (Research Assistant Professor), Ya-Ping Jiang (Research Scientist), Elzbieta Selinger (Research Support Specialist), Chia-Yen Wu (Ph.D. Student), Mohar Chattopadhy (Ph.D. Student), Jun Yong Choi (Ph.D. Student), Justin Tsai (M.S. Student)

RESEARCH INTERESTS

My laboratory's investigation concerns the intracellular signaling molecules that regulate cell growth. The focus our studies has been on phosphatidylinositol (PI) 3-kinase that produces the lipid second messenger, PI(3,4,5)P3. Dysregulation of the PI 3-kinase signaling pathway is involved in the development of cancer and diabetes mellitus. Currently, we are using biochemical and molecular techniques to investigate how the various PI 3-kinase isoforms are regulated. We are also using genetically modified mice to investigate the physiological consequences of PI 3-kinase down regulation.

RECENT PUBLICATIONS

1. Ballou LM, Selinger ES, Choi JY, Drueckhammer DG and Lin RZ. Inhibition of Mammalian Target of Rapamycin Signaling by 2-(Morpholin-1-yl)pyrimido[2,1-]isoquinolin-4-one. J. Biol. Chem., epublished June 11, 2007.
2. Said SI, Hamidi SA, Dickman KG, Szema AM, Lyubsky S, Lin RZ, Jiang Y-P, Chen JJ, Waschek JA and Kort S. Moderate pulmonary arterial hypertension in male mice lacking the vasoactive intestinal peptide gene. Circulation, 115:1260-1268, 2007.
3. Jiang Y-P, Ballou LM, Lu Z, Wan L, Kelly DJ, Cohen IS and Lin RZ. Reversible heart failure in Galpha(q) mice. J. Biol. Chem., 281:29988-29992, 2006.
4. Ballou LM, Chattopadhyay M, Li Y, Scarlata, S and Lin RZ. Galpha(q) binds to p110alpha/p85alpha phosphoinositide 3-kinase and displaces Ras. Biochem. J., 394:557-562, 2006.
5. Lu Z, Jiang Y-P, Ballou LM, Cohen IS and Lin RZ. Galpha(q) inhibits cardiac L-type Ca2+ channels through phosphatidylinositol 3-kinase. J. Biol. Chem., 280:40347-40354, 2005.
6. Fan G, Jiang Y-P, Lu Z, Martin DW, Kelly DJ, Zuckerman JM, Ballou LM, Cohen IS and Lin RZ. A transgenic model of heart failure using inducible Galpha(q). J. Biol. Chem., 280:40337-40346, 2005.
7. Garcia BG, Wei Y, Moron JA, Lin RZ, Javitch JA and Galli A. Akt is essential for insulin modulation of amphetamine-induced human dopamine transporter cell-surface redistribution. Mol. Pharmacol., 68:102-109, 2005.
8. Fan G, Ballou LM and Lin RZ. Phospholipase C-independent activation of glycogen synthase kinase-3beta and C-terminal Src kinase by Galpha(q). J. Biol. Chem., 278:52432-52436, 2003.
9. Ballou LM, Jiang Y-P, Du G, Frohman MA and Lin RZ. Ca2+- and phospholipase D-dependent and -independent pathways activate mTOR signaling. FEBS Lett., 550:51-56, 2003.
10. Ballou LM, Lin H-Y, Fan G, Jiang Y-P and Lin RZ. Activated Galpha(q) inhibits p110alpha phosphatidylinositol 3-kinase and Akt. J. Biol . Chem., 278:23472-23479, 2003.
11. Lin H-Y, Ballou LM and Lin RZ. Stimulation of the alpha1A adrenergic receptor inhibits PDGF-induced PDGF receptor Tyr751 phosphorylation and PI 3-kinase activation. FEBS Lett., 540:106-110, 2003.